286
Participants
Start Date
February 28, 2013
Primary Completion Date
November 30, 2020
Study Completion Date
November 30, 2020
ORACEA®
ORACEA® (40mg doxycycline) capsule daily for 24 months
Placebo
Placebo capsule daily for 24 months
MaculaCare, New York
Vitreous Retina Macula Consultants of New York, New York
Retina Associates of Western New York, Rochester
Associates in Ophthalmology, Ltd, West Mifflin
University of Pittsburgh Eye Center, Pittsburgh
Pennsylvania Retina Specialists, PC, Camp Hill
Mid Atlantic Retina / Wills Eye Institute, Philadelphia
George Washington University, Washington D.C.
Virginia Retina Center, Warrenton
University of Virginia, Charlottesville
Wagner Macula & Retina Center, Virginia Beach
Retina Cosultants, Charleston
Medical Center Eye Institute / Gulf Region Clinical Research Institute, Pensacola
Retina Group of Florida, Fort Lauderdale
Retina Vitreous Associates of Florida, St. Petersburg
Retina Associates of Kentucky, Lexington
Cole Eye Institute / Cleveland Clinic Foundation, Cleveland
Retina Specialists of Michigan, Grand Rapids
Retina Center, Minneapolis
Gailey Eye Clinic, Bloomington
Lifelong Vision Foundation, Chesterfield
Retina Associates of South Texas, San Antonio
Brian B. Berger, MD and Associates / Retina Research Center, Austin
Retina Research Institute of Texas, Abilene
Eldorado Retina Associates, Louisville
Colorado Retina Associates, PC, Golden
Macula and Retina Institute, Glendale
Retina Consultants of San Diego, Poway
Oregon Retina, Eugene
New England Retina Associates, Hamden
New England Eye Center at Tufts Medical Center, Boston
Harvard Vanguard Medical Associates, Boston
Vitreo-Retinal Associates, Worcester
Delaware Valley Retina Associates, Lawrenceville
Retinal and Ophthalmic Consultants, Northfield
New Jersey Retina, Toms River
New York Eye and Ear, New York
MEDARVA Foundation
UNKNOWN
Paul Yates, MD, PhD
OTHER